Kidney Disease News and Research

RSS

First ESC recommendations for patients with cardiac arrhythmias, CKD published in EP Europace

The first ESC recommendations for patients with cardiac arrhythmias and chronic kidney disease (CKD) are presented today at EHRA EUROPACE - CARDIOSTIM 2015 and published in EP Europace.

24 Jun 2015

Patient survival rates for home hemodialysis significantly higher than peritoneal dialysis

NxStage Medical, Inc. is encouraging patients to take control of their dialysis therapy and consider home hemodialysis in the wake of a new study that found patient survivability rates are significantly higher with home hemodialysis (HHD) than peritoneal dialysis (PD).

18 Jun 2015

AstraZeneca, Inserm to investigate new therapeutic approaches to type 2 diabetes, CKD

AstraZeneca today announced a three-year research collaboration with the French National Institute of Health and Medical Research (Inserm) to investigate new therapeutic approaches totype 2 diabetes and Chronic Kidney Disease.

18 Jun 2015

University of Michigan, AstraZeneca team up to identify novel targets for chronic kidney disease

AstraZeneca today announced a two-year research collaboration with the University of Michigan to advance the treatment of chronic kidney disease (CKD) through the improved understanding of the disease. The collaboration will tackle the challenging area of identifying novel targets for the treatment of CKD, focusing on the use ofpatient tissue and validation of preclinical models.

18 Jun 2015

Link between poverty and kidney disease changes over time, shows study

Poverty is known to be a strong risk factor for end-stage kidney disease. Now, a first of-its-kind study has found that the association between poverty and kidney disease changes over time.

17 Jun 2015

Link between poverty and kidney disease changes over time, study finds

Poverty is known to be a strong risk factor for end-stage kidney disease. Now, a first of-its-kind study has found that the association between poverty and kidney disease changes over time.

16 Jun 2015

New technique slows progression of polycystic kidney disease in mice

A new technique for treating polycystic kidney disease has been identified by researchers based at the UCL Institute of Child Health. Published in the Journal of the American Society of Nephrology, the treatment, which involves targeting tiny blood and lymphatic vessels inside the kidneys, is shown to improve renal function and slow progression of disease in mice.

8 Jun 2015

Withholding ARBs for longer than two days after surgery significantly increases risk of postoperative death

Withholding angiotensin receptor blockers (ARBs) for longer than two days after surgery is associated with a significantly increased risk of postoperative death, according to a study of more than 30,000 patients in the VA health care system by researchers at UC San Francisco and the San Francisco VA Medical Center.

5 Jun 2015

Regulus Therapeutics begins RG-012 Phase I clinical study for treatment of Alport syndrome

Regulus Therapeutics Inc., a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs, announced today that dosing has begun in a first-in-human Phase I clinical study of RG-012, a single stranded, chemically modified oligonucleotide that binds to and inhibits the function of microRNA-21 ("miR-21").

4 Jun 2015

Manchester, UCL researchers discover new technique for treating polycystic kidney disease

A new technique for treating polycystic kidney disease has been identified by researchers at The University of Manchester and UCL.

3 Jun 2015

New data on Resverlogix RVX-208 for CKD treatment presented at ERA-EDTA Congress

Resverlogix Corp. today announced that new data on RVX-208 was presented at the ERA-EDTA Congress in London, England in a poster entitled: "Effects of RVX-208, a First-in-Class Epigenetic BET-Inhibitor, on Key Renal Parameters in Subjects with a History of CVD, and Chronic Kidney Disease (CKD); a Post-hoc Analysis of Patients from the ASSERT, SUSTAIN and ASSURE Clinical Trials."

1 Jun 2015

Lancet Diabetes & Endocrinology to publish paper on eGFR and albuminuria for prediction of cardiovascular outcomes

The Lancet Diabetes & Endocrinology is pleased to announce that the following paper will be published to coincide with presentation at the 52nd ERA-EDTA Congress, taking place in London, UK, May 28 - 31, 2015.

1 Jun 2015

Astute Medical's NephroCheck Test obtains measurements of two biomarkers that act as alarm for AKI risk

An intervention known as remote ischemic preconditioning (RIPC) significantly reduced the occurrence of acute kidney injury (AKI) in cardiac surgery patients and confirmed that post-operative elevations of two kidney biomarkers act as an alarm for risk of AKI, according to a study published online today in the Journal of the American Medical Association.

30 May 2015

Positive results from pacritinib Phase 3 trial for treatment of myelofibrosis presented at ASCO 2015

CTI BioPharma Corp. and Baxter International's Bioscience business today announced data from PERSIST-1 – a randomized Phase 3 registration-directed trial examining pacritinib for the treatment of myelofibrosis – in a late-breaking oral session at the 51st Annual Meeting of the American Society of Clinical Oncology, May 29-June 2, 2015 in Chicago, Ill.

30 May 2015

UH researchers identify new method to provide diagnostic information on kidney disease

University of Houston researchers have identified a new, less-invasive method to provide diagnostic information on kidney disease and its severity.

30 May 2015

Measuring kidney function and damage may help predict people at risk for heart disease

Simple measures of kidney function and damage may be just as good at predicting who is at risk for heart failure and death from heart attack and stroke as traditional tests of cholesterol levels and blood pressure, new Johns Hopkins Bloomberg School of Public Health-led research suggests.

29 May 2015

First European approval of drug to treat genetic kidney disease ADPKD

Otsuka Pharmaceutical Co., Ltd. announced that the European Commission has granted marketing authorisation for JINARC® (tolvaptan) for the treatment of ADPKD in adults who have chronic kidney disease (CKD) stage one to three at initiation of treatment with evidence of rapidly progressing disease

29 May 2015

Amgen announces AMG 416 Phase 3 results for treatment of secondary hyperparathyroidism in CKD patients

Amgen today announced pooled data from two pivotal Phase 3, global, randomized, placebo-controlled trials evaluating AMG 416, a novel calcimimetic, for the treatment of secondary hyperparathyroidism in patients with chronic kidney disease (CKD) receiving hemodialysis.

29 May 2015

DaVita Clinical Research announces expansion of clinical trials capabilities in Europe

DaVita Clinical Research (DCR), a specialty contract research organization with services spanning a broad spectrum of drug and device development, today announced an expansion of its clinical trials capabilities in Europe.

28 May 2015

CVRx announces presentation of positive data from Barostim Therapy for Heart Failure clinical trial at HRS 2015

CVRx, Inc., a private medical device company, announced that positive results from the 'Barostim Therapy for Heart Failure' randomized, controlled clinical trial were presented at the 2015 annual Scientific Sessions of the Heart Rhythm Society (HRS) in a Late-Breaking Clinical Trial Session. Results were presented by Dr. Michael Zile from the Medical University of South Carolina.

26 May 2015

Kidney Disease News and Research

First ESC recommendations for patients with cardiac arrhythmias, CKD published in EP Europace

Patient survival rates for home hemodialysis significantly higher than peritoneal dialysis

AstraZeneca, Inserm to investigate new therapeutic approaches to type 2 diabetes, CKD

University of Michigan, AstraZeneca team up to identify novel targets for chronic kidney disease

Link between poverty and kidney disease changes over time, shows study

Link between poverty and kidney disease changes over time, study finds

New technique slows progression of polycystic kidney disease in mice

Withholding ARBs for longer than two days after surgery significantly increases risk of postoperative death

Regulus Therapeutics begins RG-012 Phase I clinical study for treatment of Alport syndrome

Manchester, UCL researchers discover new technique for treating polycystic kidney disease

New data on Resverlogix RVX-208 for CKD treatment presented at ERA-EDTA Congress

Lancet Diabetes & Endocrinology to publish paper on eGFR and albuminuria for prediction of cardiovascular outcomes

Astute Medical's NephroCheck Test obtains measurements of two biomarkers that act as alarm for AKI risk

Positive results from pacritinib Phase 3 trial for treatment of myelofibrosis presented at ASCO 2015

UH researchers identify new method to provide diagnostic information on kidney disease

Measuring kidney function and damage may help predict people at risk for heart disease

First European approval of drug to treat genetic kidney disease ADPKD

Amgen announces AMG 416 Phase 3 results for treatment of secondary hyperparathyroidism in CKD patients

DaVita Clinical Research announces expansion of clinical trials capabilities in Europe

CVRx announces presentation of positive data from Barostim Therapy for Heart Failure clinical trial at HRS 2015

Shaping the Future of Neuroscience: A Conversation with Atlas Antibodies on the MolBoolean™ and the Impact of SfN 2024

How the Arts Reshape Brain Function: Susan Magsamen on the Future of Neuroaesthetics

Inside the Alzheimer's Association: Dr. Heather Snyder on Driving Research and Collaboration

Latest News